Previous antiretroviral drug use compromises standard first-line HIV therapy and is mediated through drug-resistance

In ART programs in sub-Saharan Africa, a growing proportion of HIV-infected persons initiating first-line antiretroviral therapy (ART) have a history of prior antiretroviral drug use (PAU). We assessed the effect of PAU on the risk of pre-treatment drug resistance (PDR) and virological failure (VF)...

Full description

Bibliographic Details
Authors: Inzaule, Seth C., Kityo, Cissy M., Siwale, Margaret, Akanmu, Alani Sulaimon, Wellington, Maureen, Jager, Marleen de, Ive, Prudence, Mandaliya, Kishor, Stevens, Wendy, Boender, T. Sonia, Ondoa, Pascale, Sigaloff, Kim C. E., Naniche, Denise, Rinke de Wit, Tobias F., Hamers, Raph L.
Format: article
Status:Published version
Publication Date:2018
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/134539
Online Access:https://hdl.handle.net/2445/134539
Access Level:Open access
Keyword:Infeccions per VIH
Àfrica subsahariana
Antiretrovirals
HIV infections
Sub-Saharan Africa
Antiretroviral agents
Description
Summary:In ART programs in sub-Saharan Africa, a growing proportion of HIV-infected persons initiating first-line antiretroviral therapy (ART) have a history of prior antiretroviral drug use (PAU). We assessed the effect of PAU on the risk of pre-treatment drug resistance (PDR) and virological failure (VF) in a multicountry cohort of HIV-infected adults initiated on a standard non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART. Multivariate logistic regression was used to assess the associations between PAU, PDR and VF (defined as viral load ≥400 cps/mL). Causal mediation analysis was used to assess the proportion of the effect of PAU on VF that could be eliminated by intervening on PDR. Of 2737 participants, 122 (4.5%) had a history of PAU. Participants with PAU had a 7.2-fold (95% CI 4.4–11.7) risk of carrying PDR and a 3.1-fold (95% CI 1.6–6.1) increased risk of VF, compared to antiretroviral-naïve participants. Controlling for PDR would eliminate nearly half the effect of PAU on the risk of VF. Patients with a history of PAU are at increased risk of ART failure, which is to a large extent attributable to PDR. These findings support the recent WHO recommendations for use of differentiated, non-NNRTI-based empiric first-line therapy in patients with PAU.

Similar Items